Clene shares are trading higher after the company's CNM-Au8 treatment demonstrated a statistically significant reduction of plasma neurofilament light chain levels compared to placebo at 24 weeks.
Portfolio Pulse from Benzinga Newsdesk
Clene's CNM-Au8 treatment showed a statistically significant reduction of plasma neurofilament light chain levels compared to placebo at 24 weeks, leading to higher trading of Clene shares.
June 15, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clene's CNM-Au8 treatment demonstrated positive results, leading to higher trading of the company's shares.
The positive results of Clene's CNM-Au8 treatment indicate a potential increase in the company's value and demand for its shares. This directly impacts the stock price, leading to higher trading of CLNN shares in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100